Synaptopathy research is defining the path toward hearing preventive care

In my last post, I explored how audiology became centered on devices that address the hearing disability post hoc, after the fact, in parallel with research that was exploring the metabolic biology of hearing and developing the underlying oxidative stress model of cochlear dysfunction. Here, I explore what research has discovered about early stage auditory system functional decline, called synaptopathy or hidden hearing loss, and how a recent peer-reviewed paper by Keith Darrow, Douglas Beck, and William Slattery in the Journal of Otolaryngology-ENT Research helps to bring the research literature on synaptopathy into the clinical audiology mainstream ^[1].

Auditory decline before the audiogram

The major point from their paper is that auditory decline begins decades before conventional hearing tests detect it. They report up to seventy to eighty percent of cochlear nerve fibers can be lost before the audiogram registers anything at all. That big percentage is not a human measurement, but it isn't a wild, unsupported claim, either. Instead, it is a reasonable, indirect inference from lab research, mostly on mice, where researchers use histology, microscopic anatomy, to correlate cochlear tissues post-mortem with audiogram readings collected before death.

Where physics becomes metabolic biology

The number is derived from work largely associated with Sharon Kujawa and Charles Liberman, whose 2009 paper in the Journal of Neuroscience introduced the concept of cochlear synaptopathy ^[2], and whose 2015 follow-up in Hearing Research broadened the implications to noise exposure and aging ^[3]. The mechanism they describe is the gradual loss of synapses between inner hair cells and auditory nerve fibers. These synapses are the connection point where the physics of sound becomes the metabolic biology of hearing.

Signal quality, not just sensitivity

Synaptopathy degrades signal quality before it degrades sensitivity. When these synapses degrade, the signal that reaches the brain becomes noisier and less reliable, even when threshold sensitivity remains within the normal range. The audiogram is a loudness detection assessment: Can you hear this tone at this volume? It is not a signal quality assessment: How cleanly does that tone arrive in your brain?

The intervention window is wide open

Synaptopathy is biological by definition, its clinical implications are not subtle, and the intervention window is wide open: Functional symptoms like tinnitus and difficulty hearing in noise are often synaptopathy biomarkers that can progress undetected and untreated for decades. The early metabolic decline that the audiogram misses is the upstream cause of a downstream cognitive outcome that compromises quality of life and costs the global economy trillions.

Dementia, the ACHIEVE study, and the cognitive evidence

Darrow and colleagues see the consequences of missing the hidden hearing loss window through the Lancet Commission's work on modifiable dementia risk. In three reports, the Commission has identified untreated hearing loss as the largest modifiable risk factor for dementia ^{[4, 5, 6]}. The ACHIEVE trial, published in 2023, reported another large number, 48% reduction in three-year cognitive decline in at-risk older adults who received hearing intervention, one of the largest cognitive protection effects from any non-pharmacological intervention ever reported in a well-designed trial ^[7].

Darrow and colleagues are clear about the science; their paper concludes by recommending hearing aids. They do not argue that audiology needs to stretch beyond the current device-and-counseling clinical framework and toolkit and respond to the metabolic biology findings in synaptopathy research with upstream interventions that offer continuous, undramatic, biological maintenance of the auditory system. That is my argument and the topic of my next post.

References

1. Keith Darrow et al., "A clinical perspective: untreated hearing loss and cognitive decline." Link
2. Kujawa, S.G., & Liberman, M.C. (2009). Adding insult to injury: Cochlear nerve degeneration after "temporary" noise-induced hearing loss. Journal of Neuroscience, 29(45), 14077–14085. Link
3. Kujawa, S.G., & Liberman, M.C. (2015). Synaptopathy in the noise-exposed and aging cochlea: Primary neural degeneration in acquired sensorineural hearing loss. Hearing Research, 330, 191–199.
4. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6
5. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6 Link
6. Levett BA, Chandra A, Jiang J, et al. Hearing impairment and dementia: cause, catalyst or consequence? J Neurol. 2025;272(6):402. doi:10.1007/s00415-025-13140-x Link
7. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786-797. doi:10.1016/S0140-6736(23)01406-X Link